Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1990-11-15
|
| pubmed:abstractText |
1. B-85-0040 is a new cisplatin analogue with dose limiting myelosuppression. 2. The maximum tolerated dose ranges between 300 and 525 mg/kg for single i.p. bolus injection in mice. 3. Its toxicity is circadian-stage dependent with optimal tolerance between 16 and 17 hours after lights on. 4. B-85-0040 is active in L1210 leukemia. Anti-tumor activity seems to be unrelated to the circadian stage of treatment. Optimal drug timing can therefore increase its therapeutic index.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0361-7742
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
341A
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
11-20
|
| pubmed:dateRevised |
2003-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:2217224-Animals,
pubmed-meshheading:2217224-Bone Marrow,
pubmed-meshheading:2217224-Circadian Rhythm,
pubmed-meshheading:2217224-Cisplatin,
pubmed-meshheading:2217224-Drug Administration Schedule,
pubmed-meshheading:2217224-Drug Tolerance,
pubmed-meshheading:2217224-Female,
pubmed-meshheading:2217224-Lethal Dose 50,
pubmed-meshheading:2217224-Leukemia L1210,
pubmed-meshheading:2217224-Mice,
pubmed-meshheading:2217224-Mice, Inbred DBA
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Improved therapeutic index of cisplatin analogue: B-85-0040 by circadian timing.
|
| pubmed:affiliation |
Med. Oncology Div., Albany Medical College, NY.
|
| pubmed:publicationType |
Journal Article
|